ArticleOncogene2026
A truncated TNS3 isoform expressed in metastatic triple negative breast cancer stabilizes FAK and promotes lung metastasis.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC), particularly in metastatic cases, lacks effective therapeutic vulnerabilities. We previously identified TNS3-S as a variant of TNS3 that is selectively expressed in TNBC. Here, we show that TNS3-S expression is regulated by TGFβ signaling and CpG methylation at its regulatory region. Notably, TNS3-S expression is markedly elevated in lung-metastasized TNBC tumors compared to primary tumors. Knockout of TNS3-S suppressed lung metastasis and rendered the cells sensitive to anoikis, both of which were reversed by rescued expression of TNS3-S. Mechanistically, TNS3-S stabilizes focal adhesion kinase, thereby facilitating adhesion-mediated proliferative signaling. Exploratory analyses of TCGA cohorts suggested that reduced promoter CpG methylation correlates with increased TNS3-S expression and could be associated with poorer outcomes across several cancer types. Collectively, these findings identify TNS3-S as a metastasis-associated regulator that promotes tumor outgrowth in distant organs and raise the possibility that epigenetic de-repression contributes to its activation during disease progression.
Indexed as
Identifiers
42432329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.